These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28049280)

  • 1. New therapeutic agents in diabetic nephropathy.
    Kim Y; Park CW
    Korean J Intern Med; 2017 Jan; 32(1):11-25. PubMed ID: 28049280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Management of Diabetic Nephropathy.
    Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
    Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid.
    Mao ZM; Shen SM; Wan YG; Sun W; Chen HL; Huang MM; Yang JJ; Wu W; Tang HT; Tang RM
    J Ethnopharmacol; 2015 Sep; 173():256-65. PubMed ID: 26226437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
    MacIsaac RJ; Thomas MC
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):321-323. PubMed ID: 29321176
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update.
    Bhattacharjee N; Barma S; Konwar N; Dewanjee S; Manna P
    Eur J Pharmacol; 2016 Nov; 791():8-24. PubMed ID: 27568833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
    Ge J; Miao JJ; Sun XY; Yu JY
    J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic nephropathy: A potential savior with 'rotten-egg' smell.
    Dugbartey GJ
    Pharmacol Rep; 2017 Apr; 69(2):331-339. PubMed ID: 28183033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMPK allostery: A therapeutic target for the management/treatment of diabetic nephropathy.
    Ayinde KS; Olaoba OT; Ibrahim B; Lei D; Lu Q; Yin X; Adelusi TI
    Life Sci; 2020 Nov; 261():118455. PubMed ID: 32956662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic nephropathy: An update on pathogenesis and drug development.
    A/L B Vasanth Rao VR; Tan SH; Candasamy M; Bhattamisra SK
    Diabetes Metab Syndr; 2019; 13(1):754-762. PubMed ID: 30641802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.
    Mahfoz AM; El-Latif HA; Ahmed LA; Hassanein NM; Shoka AA
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1315-1324. PubMed ID: 27612855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting inflammation in diabetic nephropathy: a tale of hope.
    Moreno JA; Gomez-Guerrero C; Mas S; Sanz AB; Lorenzo O; Ruiz-Ortega M; Opazo L; Mezzano S; Egido J
    Expert Opin Investig Drugs; 2018 Nov; 27(11):917-930. PubMed ID: 30334635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives.
    Lv M; Chen Z; Hu G; Li Q
    Drug Discov Today; 2015 Mar; 20(3):332-46. PubMed ID: 25448752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timosaponin B-II ameliorates diabetic nephropathy via TXNIP, mTOR, and NF-κB signaling pathways in alloxan-induced mice.
    Yuan YL; Guo CR; Cui LL; Ruan SX; Zhang CF; Ji D; Yang ZL; Li F
    Drug Des Devel Ther; 2015; 9():6247-58. PubMed ID: 26664046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View.
    Lambers Heerspink HJ; Gansevoort RT
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1079-88. PubMed ID: 25887073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic nephropathy and multiorgan protection. Part II.
    Gluhovschi G; Gluhovschi C; Vlad A; Timar R; Bob F; Velciov S; Bozdog G; Petrica L
    Rom J Intern Med; 2011; 49(4):237-49. PubMed ID: 22568268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic Nephropathy: a Tangled Web to Unweave.
    Magee C; Grieve DJ; Watson CJ; Brazil DP
    Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):579-592. PubMed ID: 28956186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
    Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
    J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic nephropathy -- a multifaceted target of new therapies.
    Choudhury D; Tuncel M; Levi M
    Discov Med; 2010 Nov; 10(54):406-15. PubMed ID: 21122472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.
    Zain M; Awan FR
    Pak J Pharm Sci; 2014 Sep; 27(5):1379-91. PubMed ID: 25176370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terpene glycoside component from Moutan Cortex ameliorates diabetic nephropathy by regulating endoplasmic reticulum stress-related inflammatory responses.
    Chen J; Hou XF; Wang G; Zhong QX; Liu Y; Qiu HH; Yang N; Gu JF; Wang CF; Zhang L; Song J; Huang LQ; Jia XB; Zhang MH; Feng L
    J Ethnopharmacol; 2016 Dec; 193():433-444. PubMed ID: 27664441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.